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Abstract 
Problem. Patients in rural or medically underserved areas (MUAs) with inflammatory 
bowel disease (IBD) have limited access to primary care preventative services, making 
them even less likely to obtain preventative care, placing them at even greater risk for 
adverse health outcomes. 
Methods. A two-phase retrospective chart review utilizing a convenience sample of 
patients diagnosed with IBD from a privately-owned gastroenterology office to evaluate 
the effectiveness of increasing preventative screenings for IBD patients. The first review 
included 53 patients seen from January to April 2019. A preventative screening 
evaluation tool (PSET) was developed based on literature recommendations, including 
the American College of Gastroenterology (ACG) and the Crohn's and Colitis Foundation 
guidelines and implemented prior to the second review of 57 patients during the same 
time frame in 2020. 
Results: The results of this study indicated that the use of a preventative screening 
evaluation tool does increase preventative screenings in patients with IBD. The findings 
of this study demonstrated a statistically significant difference for 17 of the 25 variables 
pre- and post-implementation of the evaluation tool. 
Implications. Due to immunosuppressant medications, IBD patients are already at an 
increased risk for infections and cancers (Long et al., 2010; Melmed et al., 2006). 
Screenings for chronic conditions like heart disease, cancer, and vaccination-preventable 
infections decrease the probability of complications from chronic conditions and reduce 
the burden that patients face associated with the management of their disease. 
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Bridging the Gap in Primary Care of Inflammatory Bowel Disease Patients  
According to the Centers for Disease Control and Prevention (2019), 
inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, 
currently affects more than 3 million adults in the United States. Furthermore, the 
prevalence of IBD has been increasing substantially since 1990 and is at an all-time high 
worldwide. IBD is a chronic autoimmune disease posing health and economic burdens 
while substantially reducing patients' quality of life. The world healthcare systems face 
the continual rising challenges associated with chronic disease management, including 
primary care for patients with IBD (Institute for Health Metrics and Evaluation [IHME], 
2019). Overall, patients with IBD are not obtaining preventative services to the same 
degree as the general patient population (Farraye, Melmed, Lichtenstein, & Kane, 2017; 
Selby et al., 2008).  Lack of preventative services presents a unique challenge for patients 
with IBD for many reasons. IBD patients are often treated with immunosuppressant 
agents such as immunomodulators or biologics. Immunosuppressant agents place IBD 
patients at an increased risk of developing certain types of cancers and infections. 
Therefore, preventative services allowing for timely detection are vital in addressing such 
issues (Farraye et al., 2017; Wasan, Coukos, & Farraye, 2011).   
Evidence suggests that primary care is an essential component of care for patients 
with IBD. There are four main characteristics of primary care: initial care contact, 
continued care, comprehensiveness of care, and coordination of care with other health 
entities (Starfield, as cited in Bodenheimer & Pham, 2010). Often barriers to access 
interrupt one or more of the four main characteristics. However, there are multiple 
barriers to patients receiving adequate primary care services.  One significant barrier 
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involves geographic location.  People in the United States who live in rural or medically 
underserved areas (MUAs) experience more barriers to healthcare access than those 
living in urban areas (Logan, Guo, Dodd, Muller, & Riley III, 2013).  
Many challenges have been identified in the literature regarding barriers faced by 
rural and MUA residents.  These challenges can be attributed to a shortage of primary 
care providers (PCP), lack of insurance, financial cost, waiting time to see a PCP, 
primary care hours of operation, and issues with access to a provider which may be due 
to either the provider not taking new patients or geographic location (Douthit, Kiv, 
Dwolatzky, & Biswas, 2015; Spetz & Muench, 2018).  According to Bennett, Munkholm, 
& Andrews (2015), few evaluation tools for the management of IBD exist for PCPs, and 
little data has been published regarding the usefulness of such tools. The purpose of this 
evidence-based quality improvement (QI) project is to incorporate an evaluation tool to 
assess IBD patients for preventative services in a gastroenterologist (GI) office located in 
an MUA in Missouri (Health Resource and Administration, n. d.)  serving patients from 
the surrounding rural areas. The aim of this QI project is to increase preventative 
screening in IBD patients in a gastroenterology practice. The study question addressed in 
this QI project is as follows: 
1. Will the implementation of an IBD Preventative Screening Evaluation Tool 
increase the number of IBD patients evaluated for preventative care services 
during a three-month period compared to a similar three-month period prior to 
the implementation of the IBD Preventative Screening Evaluation Tool? 
Literature Review 
A two-phased review of the literature was conducted. The first phase was  
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conducted between August and September of 2019 and focused on the routine care for 
clients with IBD. The EBSCOhost platform was searched using the databases the 
Medical Literature and Retrieval System Online (Medline) and the Cumulative Index to 
Nursing and Allied Health Literature (CINAHL). The searches included the keywords 
routine care for patients with IBD, Preventative care AND inflammatory bowel disease 
or ibd or ulcerative colitis or Crohn's disease, primary care AND inflammatory bowel 
disease or ibd or ulcerative colitis or Crohn's disease, and routine care AND 
inflammatory bowel disease or ibd or ulcerative colitis or Crohn’s disease. The inclusion 
criteria were articles published between 1999 and 2019, English language, and peer-
reviewed. Exclusion criteria included articles not in English, articles written prior to 
1999, and articles not pertaining to IBD patients. The initial search yielded 839 articles. 
Seventeen articles were selected for abstract review based upon a title that focused upon 
routine or primary care of patients with IBD.  Ultimately, nine of the seventeen articles 
met inclusion criteria and were chosen for the literature review.  
The second phase of the literature review was performed between September and 
October 2019 and focused on rural or medically underserved areas and barriers to 
primary care access. The EBSCOhost platform was searched using the databases 
Medline, CINAHL, and PubMed. The searches included the terms medically underserved 
areas AND rural, Barriers to primary care access AND medically underserved areas, 
and barriers to primary care access in medically underserved areas. The inclusion 
criteria were articles published between 2009 to 2019 and written in the English 
language. The initial searches yielded a total of 4195 articles. Sixty-one articles were 
selected for abstract review based upon the title. Six of the sixty-one articles met  
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inclusion criteria and were chosen for the literature review (Appendix A).  
IBD Burden 
According to the IHME (2019), IBD, a chronic autoimmune disease, has 
significantly increased in prevalence, rising from 79.5 per 100,000 population in 1990 to 
84.3 per 100,000 population in 2017. Although the rate of fatality has decreased in IBD 
patients, most likely due to the increased use of immunomodulators, the rate of disability 
has risen and continues to grow. IBD occurs during the most productive time of life, 
typically affecting individuals anywhere from their second to the fourth decade of life.  It 
can impact every aspect of an individual’s life (physical, psychological, social, and 
familial) and may lead to increased rates of anxiety and depression. Further, IBD poses 
significant challenges to both clients and healthcare providers associated with disease 
management (IHME, 2019). 
Primary Care Barriers 
One significant barrier to primary care is a shortage of PCPs. A shortage of more 
than 20,000 PCPs is predicted by 2025 (Health Resources and Services Administration, 
as cited in Spetz & Muench, 2018). The shortage of PCPs has significantly increased over 
the years due to a decline in physicians choosing primary care (Fancher et al., 2011; 
Spetz & Muench, 2018). Other reasons for a shortage of PCPs is an increase in the 
geriatric population, an increase in chronic diseases, and an increase in more people 
having insurance coverage due to the Affordable Care Act (Spetz & Muench, 2018). 
Another significant factor contributing to the shortage of PCPs is the lack of full practice 
privileges for nurse practitioners (Ortiz et al., 2018). In addition, many clients experience 
barriers that stem from the high cost of medical care or the lack of healthcare insurance.  
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Lack of insurance may prevent many clients from being seen by a PCP. This can be even 
further compounded by clients in MUAs who also do not have the means for reliable 
transportation (Hefner, Wexler, & McAlearnery, 2015). 
Rural and MUA 
Rural Americans experience a greater amount of chronic disease and poorer 
health outcomes than their urban counterparts (Douthit et al., 2015). An increase in 
chronic disease and poorer health outcomes are partly due to the unique challenges that 
rural residents face in seeking primary care. Residents living in rural areas often face 
other factors that contribute negatively to their health status. These factors include low 
educational level, poverty, lack of employment or being underemployed, and not having 
insurance or being underinsured. Rural areas often have a higher rate of minority 
populations and a higher poverty rate than those residing in urban areas (Logan et al., 
2013).  Patients in rural or MUAs with IBD have limited access to primary care 
preventative services, making them even less likely to obtain preventative care; placing 
them at even higher risk for adverse health outcomes 
Missouri 
More than 38% of Missouri’s population lives in rural areas (Missouri Hospital 
Association [MHA], 2018). A rural area is defined by the Rural Development Act of 
1972 (as cited in Douthit et al., 2015) as an area with 10,000 or fewer residents, and a 
rural county has less than 150 people per square mile (MHA, 2018). Missouri has 101 
rural counties, and 99 of them are designated as primary medical care health professional 
shortage areas (HPSA). An HPSA indicates that the county has a shortage of PCPs and 
either dental or mental health providers (Missouri Department of Health and Senior 
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Services as cited in MHA, 2018). Many counties in Missouri are also designated as a 
MUA. To be designated as an MUA, the area must have an insufficient number of PCPs, 
a high mortality rate of infants, and either an increased poverty rate or a large population 
of elderly or both (MHA, 2018). 
Primary Care Needs   
Need for primary care with chronic disease. The prevalence of chronic disease 
is costly. Many common chronic diseases, such as diabetes, cardiovascular disease, 
cancer, and arthritis, are preventable (Logan et al., 2013). Patients with chronic 
conditions are less likely to receive preventative services than the general population, and 
IBD patients are no exception. Selby et al. (2008) demonstrated that IBD patients 
received fewer preventative services than the general population regarding 10 generally 
recognized, available, and beneficial preventative services. The 10 preventative services 
that were evaluated were blood pressure screening, non-fasting HDL, cholesterol, and 
total cholesterol, diabetes screening of hypertensive and hyperlipidemia patients, 
osteoporosis screening in women older than 65 years, mammograms in women 40 or 
older every one to two years, and pap smears every three years for ages 21 through 65, 
colon screening in those 50 years or older, dietary counseling in patients with 
cardiovascular disease, and annual flu vaccines and pneumococcal vaccine for those who 
are 65 years of age or older. 
Need for Primary Care with IBD. IBD patients are at an increased risk of 
infections due to treatment with long-term immunosuppressant medications. 
Immunosuppressant patients are not being adequately vaccinated despite guidelines to the 
contrary. Melmed et al. (2006) found in their survey study of 169 participants that even 
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though 80% of the participants saw a PCP, most did not receive adequate vaccination 
coverage. Eighty-six percent of the participants (146/169) were exposed to 
immunosuppressant medications. However, only 28% of them had received the flu 
vaccine, and eight percent had received the pneumococcal vaccine. The study also 
revealed substandard vaccination rates for varicella, hepatitis, and tetanus (Melmed et al., 
2006). 
Long et al. (2010) found in their retrospective cohort study that non-melanoma 
skin cancers (NMSC) were significantly increased for IBD patients. Patients with IBD 
are at an increased risk for non-melanoma skin cancers due to the immunosuppressant 
therapies used to treat the IBD. Long et al. (2010) found 733 cases of NMSC per 100,000 
compared to 447 cases of NMSC per 100,000 in the control group, thus demonstrating 
the need for IBD patients to receive full skin assessment screenings. 
The question is then raised as to why IBD patients are not receiving preventative 
services such as vaccinations at the same rate as general medical patients. The answer 
may be two-fold, due to uncertainty on the gastroenterologist's part as well as the 
uncertainty on the part of the PCP.  Wasan et al. (2011) found that only 12% of the 
gastroenterologists surveyed correctly recommended the appropriate vaccine to both their 
immunocompromised and immunocompetent patients. Sixty-four percent of the 
gastroenterologists responded that it was the PCP’s responsibility to determine which 
vaccine to administer, and 83% answered that it was the PCP’s responsibility to 
administer the vaccine (Wasan et al., 2011). Selby, Hoellein, and Wilson (2010) found 
that PCPs are uncomfortable recommending vaccines to IBD patients, stating 
unfamiliarity with IBD medications as the primary reason for being uncomfortable. 
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Interventions and Guidelines for IBD Patients 
IBD patients often think of their gastroenterologist as their primary care provider. 
In order to increase access to preventative care, the ACG guidelines recommend that IBD 
patients be co-managed by both the gastroenterologist and the PCP (Farraye et al., 2017). 
The guidelines recommend that IBD patients should receive the appropriate vaccines 
based on age and immunocompetency status. Furthermore, whenever possible, the client 
should be vaccinated before receiving immunosuppressive therapy. The Crohn's and 
Colitis Foundation (2019) recommends the following vaccines: 
• Influenza vaccines for all patients annually  
• Pneumococcal Prevnar © (PVC13) to all patients 65 years of age, followed by the 
pneumococcal Pneumovax © (PPSV23) one year later 
•  For patients 19 and older who are immunosuppressed PVC13 vaccine followed 
eight weeks later by the PPSV23 with the second dose of PPSV23 given five 
years after the initial dose  
• Tetanus and diphtheria toxoids with acellular pertussis (Tdap) vaccine to all 
patients 19 years of age or older if not vaccinated previously 
• Booster of tetanus and diphtheria toxoid (Td) every 10 years  
• Human papillomavirus (HPV) for all males and females 9-26 years of age in a 
two-three dose series 
• Group B meningococcal meningitis for ages 16-23 for patients at high risk  
• Hepatitis A and B for all patients 
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• Measles, mumps, and rubella (MMR) and varicella vaccines both; two-dose series 
vaccines given four weeks apart for all non-immune patients prior to initiation of 
immunosuppressant therapy  
The Crohn's and Colitis Foundation has specific recommendations for female clients. 
It is recommended that all women have annual cervical cancer screenings. DEXA scans 
are recommended for women 65 and older or for any age who are at high risk for 
osteoporosis. Purified protein derivative (PPD) or interferon-gamma release assay 
(IGRA) is recommended for any patient prior to the initiation of anti-TNF or anti-IL-
12/23. Further, it is recommended that all clients are screened annually for anxiety and 
depression and have skin cancer screenings. Any patients who smoke are encouraged to 
quit. 
Implementation of an IBD Preventative Care Assessment Tool 
Although IBD patients have an increased risk of complications, they are less 
likely to receive preventative services. Previous studies have demonstrated hesitation on 
both the part of the PCP and the gastroenterologist in taking responsibility for 
preventative care for IBD patients. Valluru, Kang, and Gaidos (2018) demonstrated that 
the implementation of a health maintenance template in an outpatient GI clinic 
significantly improved compliance of documentation of preventative care services. 
Theoretical Framework 
This quality improvement project was guided by the Plan Do Study Act (PDSA) 
framework. The PDSA method is a framework that directs an approach to quality 
improvement through a four-step process. The first step is the Plan step, which mainly 
involves the aim of the project, what is being changed, and how the change is measured.  
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The second step is the Do step which consists of the implementation of the plan. The 
third step in the framework is the Study step, which consists of evaluating the change. 
What part of the change was successful, what part of the change is sustainable, and what 
interventions need to be reevaluated. The fourth and final step in the framework is the Act 
step, which consists of looking at the results and determining if any revisions are 
necessary (Bollegala et al., 2016). 
The Plan step for this project consists of developing a Preventative Screening 
Evaluation Tool (PSET) for IBD patients. The second step of Do consisted of the 
implementation of the tool and collecting the data. The third part is the Study step, which 
involved analyzing the data collected. The last step of Act is dependent on the data 
collection but involved making recommendations based upon the data findings.  
Methods 
Design 
A pre- and post-intervention evaluation using a retrospective chart review was 
used to evaluate the effectiveness of increasing preventative screening evaluation for IBD 
patients. The retrospective chart review was conducted in two phases. The first 
retrospective review of patients diagnosed with IBD was collected for the time period 
prior to the implementation of the PSET. The second review occurred after the 
implementation of the PSET. 
Setting 
The setting for this project was a privately-owned gastroenterology clinic located 
in an MUA in Southeast Missouri serving rural patients from Missouri, Illinois, 
Kentucky, and Tennessee. The clinic has approximately 2500 patients and conducts 
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approximately 4,000 visits annually. Roughly 20 percent of these patients have been 
diagnosed with IBD. The clinic has one board-certified internal medicine physician with 
a subspecialty in gastroenterology and two family nurse practitioners.  
Sample 
A convenience sample of 110 patients diagnosed with IBD from this 
gastroenterology office was used for this project. Inclusion criteria were any patient age 
18 or older who had a diagnosis of IBD and was a patient of the gastroenterology office 
seen between the time frames during which data was collected.  Exclusion criteria were 
any patients not diagnosed IBD, under the age of 18, or patients not seen within the time 
frames in which data was collected (See Table 1). 
Procedures 
A planning team was formed, which consisted of a practicing NP at the 
gastroenterology office and a DNP student who was the primary investigator (PI) 
interested in studying preventative care screenings in IBD patients. Several meetings 
were conducted in August 2019 to discuss the process. The screening tool was adapted 
from Cornerstones Health’s (2018) IBD Checklist for Monitoring and Prevention and the 
guidelines from the ACG and the recommendations of Crohn's and Colitis Foundation 
(Farraye, 2017 & Crohn's & Colitis Foundation Professional Education Committee, 
2018). After consulting with the providers, guidelines from the American Academy of 
Family Physicians [AAFP] (2019) which are based on recommendations from the United 
States Preventative Services Task Force were included for mammograms, alcohol 
screenings, and cardiovascular screenings (diabetic and lipid panels) due to their 
importance in preventative care and ease of screening.  In December of 2019, the PSET 
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was introduced, and the staff was trained on its use during a one-on-one session with the 
investigator. 
Approval Processes 
Institutional Review Board (IRB) approval was obtained from the University of  
Missouri-St. Louis (UMSL). The project qualified for exempt review. Additionally, 
permission was obtained from the gastroenterology office.  
Data Collection  
The evaluation tool was implemented on January 16th, 2020. A retrospective 
(whole) chart review was conducted from January through March of 2020 to collect data 
from patients' charts for the period of January 16th, 2019, through April 15th, 2019. A 
total of 53 patients' charts were reviewed for the pre-implementation group. The 
following demographic data were collected: the age range of the patient, the gender of the 
patient, and the ethnicity of the patient, type of IBD diagnosis the patient had (ulcerative 
colitis or Crohn's Disease), whether or not the patient had a PCP, time frame of the last 
visit with PCP.  Other data collected included a screening of what type of preventative 
health maintenance the patient had received. This study looked at 25 preventative health 
variables (See Appendix B), and whether or not the preventative health maintenance was 
up to date according to the guidelines. Only the data available during this timeframe was 
used for this project.  
The second retrospective (whole) chart review was conducted for the post-
implementation group at the end of April 2020 for the proceeding period of January 16th, 
2020, through April 15th, 2020. A total of 57 patients' charts were reviewed for the post-
implementation group. The same data and inclusion and exclusion criteria were used for 
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the post-implementation group as for the pre-implementation group. No personal 
identifiers were collected during the conduction of the chart reviews. The data collection 
tool was coded using a four-digit code known only to the primary investigator and stored 
on a password-protected flash drive. 
Data Analysis 
The dataset was analyzed using the Statistical Package for the Social Science 
(SPSS) version 26 and Intellectus Statistics (IS) was used for data interpretation. For each 
subject in the pre-implementation group, the total number of screenings that they 
received was tallied using the Data Collection Tool (Appendix B). This process was 
repeated for each subject in the post-implementation group. The data was cleaned to 
ensure that all of the variables have valid and usable values and to address any missing 
data.  
The patients' demographic characteristics were analyzed using descriptive 
statistics (Table 1). Whether or not each individual preventative screening measure was 
completed was compared between the pre-implementation and post-implementation 
groups for each preventative screening measure in the Data Collection Tool (Appendix 
B). The appropriate statistical test for analyzing each individual preventative screening 
variable was cross-tabulations, and the statistical significance determined through Chi-
square. For cases not meeting parametric assumptions, a Fisher's exact test was 
conducted.  Typically, an independent t-test is appropriate when comparing two 
population means in uncorrelated samples. Therefore, an independent t-test was deemed 
appropriate to compare the means of all variables, collectively, pre- and post-
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implementation of the screening tool. However, one or more of the required parametric 
assumptions were violated, and the Mann-Whitney Rank-Sum test was performed.  
Results  
A total of 110 patients' charts (N=110) were reviewed for this study. The 
participants' ages ranged from 18 to greater than 70 years of age, with the most common 
age range being 50-59. The participants consisted of 66.4% female (N=73), 32.7% male 
(N=36) and one (N=1, 0.09 %) not identified. The most common frequency of ethnicity 
noted in this study was Caucasian (N=101, 91.8%). African-Americans accounted for 
4.5% (N=5) of the participants seen. There were 4 (N=4, 3.6%) patients who did not have 
ethnicity identified on the chart. The most frequently observed IBD diagnosis at 71.8% 
was Crohn's disease (N=79). Frequencies were also obtained for years of diagnosis, 
whether or not the patient had a PCP, the last visit to PCP, and immunosuppression 
status. See Table 1 for details of these variables.   
A Chi-square analysis was performed on the six demographic variables (age, 
gender, years of diagnosis, PCP status, last visit to PCP, and the patient’s status for 
immunosuppression) for both pre and post groups to determine if there was a statistical 
significance between the groups. There was no statistical significance noted in the pre 
and post groups based on an alpha value of 0.05. Two of the demographic variables 
(ethnicity and diagnosis) did not meet the parametric assumptions required for a Chi-
square test. The assumption requiring that 80% of the expected cells have a value of five 
was violated. Therefore, the non-parametric Fisher's exact test was used to determine 
statistical significance, and there was no statistical difference noted. 
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The Chi-square analysis was performed on 14 variables both pre and post tool 
(varicella, MMR, Tdap/Td, hepatitis A and B vaccine, vitamin D level, a prescription for 
calcium and vitamin D, colonoscopy exam, Pap smear, full skin assessment, depression 
screening, vitamin B12 level, iron panel, and PPD or IGRA). Thirteen of the 14 variables 
analyzed using the Chi-square were statistically significant based on an alpha value of 
0.05. The only variable not significant was the depression screening with a p-value of 
.782; (Table 2). 
Eleven of the variables (Herpes zoster, influenza, HPV, meningococcal, 
pneumococcal, DEXA scan, mammogram, tobacco use and cessation screening, alcohol 
screening, lipid panel, and diabetic screening) did not meet the parametric assumptions 
required for a Chi-square test. The assumption requiring adequate cell size was violated 
either by having a cell value of zero or less than 80% of the expected cells had a value of 
less than five. Therefore, the non-parametric Fisher's exact test was used to determine 
statistical significance. The variables DEXA scan, mammogram, lipid panel, and diabetic 
screening were all statistically significant based on an alpha value of 0.05. See Table 3 
for details of the other variables.  
Out of the 25 variables evaluated, 17 of the variables showed a statistical 
significance either through the Chi-square or Fisher's exact test. Table 4 shows the 
percentages obtained for the variables, both pre and post tool implementation. Although 
only 17 of the 25 variables showed a statistical significance, Table 4 shows that screening 
for 23 out of the 25 variables increased after implementation of the PSET.  
The pre and post PSET implementation groups were compared with an 
independent t-test to evaluate any difference in the total number of variables screened. 
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There were 53 charts reviewed in the pre-group (M = 5.60, SD = 1.26) compared to the 
57 charts reviewed in the post-group (M = 11.18, SD = 7.24).  Because all of the 
assumptions were not met, the non-parametric Mann-Whitney Rank-Sum Test was 
conducted to compare the mean number of the 25 variables screened for pre- and post-
implementation of the tool. The p-value was < .001, indicating that the results were 
significant based on an alpha value of 0.05.  
Discussion 
Explanation of significance 
There was no statistical significance noted in the demographic variables between 
the pre and post tool groups. The lack of statistical significance between the pre and post 
groups, indicates that both groups were similar. Thus, validating the statistical 
significance noted with the screening variables. 
A review of the analysis indicated that the implementation of a PSET in a 
gastroenterology office did increase the number of preventative screenings obtained in 
IBD patients. The mean value (11.18) of variables screened post-tool was significantly 
higher than the mean value (5.60) of variables screened pre-tool.  
Eight of the 25 variables did not show statistical significance. Of the eight 
variables that were not statistically significant, six of the variables depression screening, 
alcohol screening, tobacco use and cessation counseling, and evaluation of the 
vaccinations for herpes zoster, influenza, and pneumococcal were screened for pre-tool 
implementation at very high rates. The remaining two variables, HPV and 
meningococcal, had a diminutive sample size of N=3 and N=4, respectively. Therefore, 
the small sample size affected the ability to obtain valid results.  
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Implications for practice 
The use of this tool is significant because it has shown an increase in the number 
of preventative screenings. The increase in preventative screenings is clinically 
significant because patients with IBD are already at an increased risk for infections and 
cancers due to the use of immunosuppressant medications (Long et al., 2010; Melmed et 
al., 2006). Screening for chronic conditions such as heart disease, cancer, diabetes, and 
vaccination-preventable infections reduces the probability of complications from chronic 
conditions and reduces the burden that IBD patients face associated with the management 
of their disease (IHME, 2019). Although a statistical significance was noted in screenings 
between the pre- and post-implementation groups, more than half of the patients in the 
post-implementation group still did not receive screenings making this clinically 
significant.  
Providers need to consider this when assessing their already high-risk IBD 
patients. If IBD patients are screened for these preventative measures, and it is 
determined that the patient is missing these preventative measures, it allows the provider 
the opportunity to educate the patient. Education should not only take place on the 
importance of preventative care in general but also the importance of preventative care 
concerning high-risk conditions like IBD. 
Limitations 
 There were several limitations to this study noted. First, the sample size was 
smaller than anticipated. The pre-implementation group n=53 was lower than expected 
because the gastroenterologist, although a long-standing physician in the community, had 
just recently opened up his own private practice. The post-implementation group n=57 
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was impacted by COVID 19. From mid-march until the end of the study in mid-April, the 
office was closed for a week. Once the office reopened, they were only operating two 
days a week for the next few weeks. Additionally, several patients canceled on the days 
that the office was opened.  
A second limitation noted was that the chart did not always distinguish between  
the PSV23 or the PCV13 pneumococcal vaccination assessed; therefore, they were 
combined for the purpose of this study. The third limitation noted was that only one of 
the three providers in the gastroenterology office was consistent with completing the 
screening form while the other two providers were inconsistent in completing the form. 
The fourth limitation was time-constraint. The providers voiced difficulty trying to fit the 
PSET into the time allowed for office visits.  
Recommendations  
AAFP (2020) conducted a survey in which 80% of 8774 physicians indicated they 
were either overextended or at their capacity to see patients. Providers indeed have a 
limited amount of time to see patients, and assessing for 25 preventative screening 
variables is time-consuming. Furthermore, it adds to the already pressed time that 
providers feel. Therefore, one recommendation is that the PSET is included in new 
patient packets. Other suggestions are that further studies be conducted to determine the 
best way for PCPs and specialists like gastroenterologists to collaborate on preventative 
care measures for their shared IBD patients. Another area for study is to establish which 
preventative measures are most clinically significant for IBD patients. Then the number 
of preventative screening variables that the gastroenterologist assesses for could be 
reduced. 
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In discussion with one of the providers, it was mentioned by the provider that they 
had not had the opportunity to use the screening forms because they had not seen any 
patients for IBD. Upon further investigation, it was noted that several of the patients had 
a history of IBD, but that was not the reason the patient was seeking care. Therefore, 
another recommendation was that a box is added to the paperwork a patient fills out when 
checking in, asking if the patient has a history of IBD.  If the patient has a history of IBD, 
then the office staff or the person rooming the patient can place a screening form on the 
patient's chart for the provider.  
Conclusion 
The results of the study demonstrated that the use of a PSET increased the number 
of IBD patients being screened for preventative care measures in a gastroenterology 
office. Patients with IBD are already at a high risk of developing chronic conditions such 
as infections and some cancers. The development of these chronic conditions, along with 
other potential preventative, chronic problems can lead to adverse health outcomes and 
complicate the management of their care. The implementation of a screening tool to 
evaluate preventative care, especially in rural or MUAs where access to primary care 
preventative services are limited, has the potential to minimize the effects of chronic 
conditions on an already vulnerable population. To ensure that vulnerable patient 
populations such as patients with IBD are receiving preventative screening evaluations, it 
is essential that PCPs and specialists such as gastroenterologists work together to co-
manage their patients’ care. 
The practice sees the value of this project but recognized the time-constraint. Due 
to the limited amount of time, the practice has decided to have all IBD patients come in 
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for a wellness specific visit once a year. During this visit, the PSET will be completed, 
and any additional screenings will be performed. The practice has created a letter to send 
to the PCP, letting them know how their office is partnering with them to take better care 
of their shared patients. The office plans to send a copy of PSET to the PCP for their 
records; this will help all providers be on the same page with managing patient care. 
Another positive outcome of this project expressed by one of the practitioners was that 
although it took longer for their visit, patients were very appreciative that the PSET had 
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     n (53)         % 
Post-Group 
    n (57)         % 
Total 
    n (110)       % 
Gender       
    Female 33 62.3 40 70.2 73 66.4 
    Male 20 37.7 16 28.1 36 32.7 
    Missing 0 0.00 1 1.8 1 0.9 
Age       
    18-29 6 11.3 3 5.3 9 8.2 
    30-39 8 15.1 11 19.3 19 17.3 
    40-49 8 15.1 14 24.6 22 20.0 
    50-59 15 28.3 14 24.6 29 26.4 
    60-69 7 13.2 10 17.5 17 15.5 
    ≥ 70 9 17.0 5 8.8 14 12.7 
Ethnicity       
    African American 4 7.5 1 1.8 5 4.5 
    Caucasian 47 88.7 54 94.7 101 91.8 
    Other 2 3.8 2 3.5 4 3.6 
Diagnosis       
    Crohn’s 39 73.6 40 70.2 79 71.8 
    Ulcerative Colitis 13 24.5 15 26.3 28 25.5 
    Both 1 1.9 2 3.5 3 2.7 
Year of Diagnosis       
    Unknown 31 58.5 39 68.4 70 63.6 
    ˂ 8 years  6 11.3 6 10.5 12 10.9 
    ≥ 8 years 16 30.2 12 21.1 28 25.5 
Immunosuppressed       
    No 20 37.7 24 42.1 44 40.4 
    Yes 32 60.4 33 57.9 65 59.1 
    Missing 1 1.9 0 0.00 1 0.9 
Primary Care Provider 
(PCP) 
    
  
    No 11 20.8 8 14.0 19 17.3 
    Yes 42 79.2 49 86.0 91 82.7 
Last Visit to PCP       
    Unknown 51 96.2 40 70.2 91 82.7 
    ≤ 1 year 2 3.8 17 29.8 19 17.3 
Note. Due to rounding errors, percentages may not equal 100%. Adapted from “Intellectus Statistics 
[Online computer software].” (2020). Intellectus Statistics. https://analyze.intellectusstatistics.com 
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Table 2. Frequencies & Statistical Significance of Variables Pre & Post Screening Tool 
Variables Screened 







 No Yes X2 df p 
Varicella 
     Pre 














     Pre 














     Pre 














     Pre 














     Pre 













Vit. D Level 
     Pre 













Rx Ca+/Vit. D 
     Pre 














     Pre 














     Pre 













Full Skin Assess. 
     Pre 














     Pre 













Vit. B12 Level 
     Pre 














     Pre 













PPD or IGRA 
     Pre 













Note. Values formatted as Observed [Expected].  
Key –  MMR: measles, mumps, and rubella; Tdap: tetanus and diphtheria toxoids with acellular pertussis 
Td: tetanus and diphtheria; Hep A: Hepatitis A; Hep B: Hepatitis B; Vit.: Vitamin; Rx: Prescription; Ca+: 
Calcium; PAP: Papanicolaou; Assess.: Assessment; Scr.: Screening; PPD: purified protein derivative; 
IGRA: Interferon Gamma Release Assay.  
Adapted from “Intellectus Statistics [Online computer software].” (2020). Intellectus Statistics. 
https://analyze.intellectusstatistics.co 
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Table 3. Observed and Expected Frequencies of Variables Screened Pre and Post Tools 
 Screened             95% CI  
Variable No Yes OR LL UL p 
Herpes Zoster       
     Pre-Tool 6[4.34] 47[48.66] 2.298 .544 9.699 .309 
     Post-Tool 3[4.66] 54[52.34]     
Influenza       
     Pre-Tool 2[1.45] 51[51.55] 2.196 .193 24.951 .608 
     Post-Tool 1[1.55] 56[55.45]     
HPV       
     Pre-Tool 2[1.5] 0[0.50] 2.000 .500 7.997 1.00 
     Post-Tool 1[1.50] 1[0.50]     
Meningococcal       
     Pre-Tool 1[0.80] 0[0.30] 1.500 .674 3.339 1.00 
     Post-Tool 2[2.30] 1[0.80]     
Pneumococcal           
     Pre-Tool 2[1.98] 41[41.02] 1.024 .138 7.620 1.00 
     Post-Tool 2[2.02] 42[41.98]     
DEXA Scan       
     Pre-Tool 29[24.70]  0[4.30] 1.324 1.121 1.563 .005 
     Post-Tool 34[38.30] 11[6.70]     
Mammogram       
     Pre-Tool 23[18.16]   0[4.84] 1.545 1.206 1.981 ˂.001 
     Post-Tool 22[26.84] 12[7.16]     
Tobacco Use/Cessations      
     Pre-Tool 0[0.50] 53[52.50] 1.018 .983 1.054 1.00 
     Post-Tool 1[0.50] 56[56.50]     
Alcohol Screening       
     Pre-Tool 2[1.45] 51[51.55] 2.196 .193 24.951 .608 
     Post-Tool 1[1.55] 56[55.45]     
Lipid Panel       
     Pre-Tool 10[6.10]     0[3.90] 2.067 1.437 2.973 .003 
     Post-Tool 15[18.90 16[12.10]     
Diabetic Screening      
     Pre-Tool 10[6.10]     0[3.90] 2.067 1.437 2.973 .003 
     Post-Tool 15[18.90] 16[12.10]     
Note. Values formatted as Observed [Expected]. OR = odds ratio; CI = confidence interval;  
LL = lower limit; UL = upper limit.  
Key – HPV: Human Papilloma Virus; Pneumococcal: Pneumococcal conjugate vaccine 
(PVC13) and pneumococcal polysaccharide vaccine (PPSV23); PAP: Papanicolaou; DEXA: 
dual-energy X-ray absorptiometry.  
Adapted from “Intellectus Statistics [Online computer software].” (2020). Intellectus Statistics. 
https://analyze.intellectusstatistics.com 
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Table 4. Variables percentage screened Pre and Post Tool with P-values 
Variables % Screened  
Pre-Tool 
% Screened  
Post-Tool 
P-Value 
Immunizations    
• Hep A 3.8 35.1 ˂.001 
• Hep B 3.8 38.6 ˂.001 
• MMR 0 31.5 ˂.001 
• Tdap/Td 0 33.3 ˂.001 
• Varicella 0 31.6 ˂.001 
• Herpes Zoster 88.7 94.7 .309 
• HPV 0 50 1.00 
• Influenza 96.2 98.2 .608 
• Meningococcal 0 33.3 1.00 
• Pneumococcal 95.3 95.5 1.00 
Bone Health    
• Vit. D Level 0 36.8 ˂.001 
• Rx Ca+/ Vit. D 2 48.2 ˂.001 
• DEXA Scan 0 24.4 .005 
Cancer Screenings    
• Colonoscopy 71.4 94.7 ˂.001 
• Full Skin Assessment 0 52.8 ˂.001 
• Mammogram 0 35.2 ˂.001 
• Pap 0 56.2 ˂.001 
Other Screenings    
• Alcohol Screening 96.2 98.2 .608 
• Depression Screening 35.8 33.3 .782 
• Diabetes Screening 0 51.6 .003 
• Lipid Panel 0 51.6 .003 
• Vitamin B12 Level 8.3 59.3 .002 
• Iron Panel 1.9 35.1 ˂.001 
• PPD or IGRA 5.7 42.1 ˂.001 
• Tobacco Use / 
Cessation 
100 98.2 1.00 
Note. Variables with only the blue screened post-tool line had 0% screened in the pre-tool.  
Key –  Hep A: Hepatitis A; Hep B: Hepatitis B; MMR: measles, mumps, and rubella; Tdap: 
tetanus and diphtheria toxoids with acellular pertussis Td: tetanus and diphtheria; HPV: Human 
Papilloma Virus; Vit.: Vitamin; Rx: Prescription; Ca+: Calcium; DEXA: dual-energy X-ray 




















































To explore what 
readily searchable 
tools, action plans, 
or guides exist for 
non-specialist for 
the care of IBD in 
comparison to other 
chronic diseases 
A literature search 
using PubMed, 





• Almost no tools exist to 
help primary care 
manage IBD patients 
• A gap exists in tools 
needed by primary care  
Recommendations 
• Tools need to be 
developed to help assist 
primary care in the 















To review the status 
of primary care in 
the United States 
and to discuss the 
projected primary 
care shortage 




• Primary care providers 
are geographically 
maldistribution  
• We are in an era of 
primary care shortage 
Recommendations 
• Increase access to 
primary care by adding 
hours (weekend and 
evening hours), institute 
open-access scheduling, 



















To identify barriers 
in seeking or 
accessing health 
care in the rural 
USA 
Studies focusing on 









• Barriers in access 
significantly affect the 




• Better representation of 
rural needs at the state 
and national level 
Fancher et al., 
2011 
The authors 
describe the efforts 
NA Not a study, 
supporting 
Results 
• Primary care careers are 

















to increase interns’ 






































• IBD patients receive 
preventative care at a 




• Annual flu vaccine, non-
live for 
immunocompromised 
patients and their 
household members 
• Receive the PCV 13 and 
PPSV23 according to 
guidelines 
• Those > 50 (even some 
immunosuppressed 
groups) need the herpes 
zoster vaccine 
• Receive the varicella 
vaccine if no previous 
exposure before 
immunosuppressive 
therapy is initiated 
• Those 
immunosuppressed and 
traveling to areas where 
yellow fever are 
prevalent need an 
infectious disease 
specialist consultation 
• Adolescents with IBD 




members can receive live 
vaccines with caution 
• Need to receive 
appropriate vaccines for 
age prior to taking 
immunosuppressant 
agents 
• Need to receive Tap, 
HAV, HBV, and HPV 
per vaccination 
guidelines 
• Annual cervical cancer 
screening for women on 
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immunosuppressant 
agents 
• Depression and anxiety 
screening for all patients 
• All patients regardless of 
their use of biologics 
need to be screened for 
melanoma 
• Patients on 
immunomodulators 
should be screened for 
non-melanoma squamous 
cell cancer 
• Screening for 
osteoporosis 
• Crohn’s Disease patients 


























reported barriers to 
accessing primary 
care by insurance 
status 
Two hospital EDs 
within a large 
academic medical 
setting using a 
convenience sample 
of 349 patients 




• Self-reported barriers to 
accessing primary care  
1. No insurance 
2. No income / 
Financial / cost 
3. Transportation 
4. No PCP 
5. Poor health condition 
6. No time 
7. Waiting time 
8. Convenient hours of 
operation 
9. Sent to ER by PCP 




12. Not fully outfitted 
• Barriers different for the 
insured (7-12) versus the 
uninsured (1-6) 
Limitations 
• Nonresponse bias by 
insurance status 
• Higher response rate by 
insured versus the non-
insured 
• Location of study in a 
single area 
Recommendations 












Report the burden 





mortality rates.  
Non-fatal burdens 
were searched using 
primary studies, 
hospital discharges, 




• Increase in prevalence of 
IBD disease since 1990 
• The death rate of IBD 
decrease since 1990 
• Approximately doubling 
of the disability-adjusted 
life years from 1990 to 
2017 



















& Riley III, 
2013 
The Burden of 
Chronic 













cancer, and arthritis) 
Telephone survey 
interviewing 2,526 






• Health disparities are a 
continual and significant 




• Oversampling of black 
males in order to 
represent the population 
demographics of rural 
Florida 
• Chronic disease was self-
reported 























consisted of 53,377 
patients with IBD 
 
Nested Case-Control 
Study consisted of 
742 cases of NMSC 






• Incidence of NMSC was 
significantly higher in 
the cohort study 




• Large sample size 
• Geographic diversity 
 
Limitations 
• Use of administrative 
data, therefore, a risk of 
misclassification of data 
• Elderly and uninsured 
not representative of the 
population studied 

















receiving care in an 
IBD specialty clinic 
169 patients at an 
IBS specialty clinic 
Survey Results 
• IBD patients are under-
vaccinated for 
preventable illnesses 




• 45% recalled a tetanus 
vaccine within the last 
ten years 
• 28% (41) regularly 
received the flu vaccine 








• 9% (13) received the 
pneumococcal vaccine 
• Reasons for not receiving 
the flu vaccine was 
unawareness (49%) and 
fear of side effects (18%) 
• 44% (75) at risk for HBV 
but only 28% (47) had 
been vaccinated  
 
Recommendation 
• Vaccinate against 
preventable illnesses 
 







IBD Patients is 
Significantly 









Assess the rate of 
IBD patients 




117 IBD patients 
from the University 
of Kentucky and 125 





• IBD patients receive 
preventative health 
services at a lower rate 
than general primary care 
patients. 
• Insurance coverage alone 
could not account for the 





• The survey was based on 
recall; therefore, the 
ability to recall may have 
affected the results 
 
• IBD patients receive 
such complex services 
that it is possible they 
may not recall some 
preventative services in 
comparison to primary 























Assess primary care 
providers attitudes 
and comfort levels 
toward preventative 
care of IBD patients  
61 primary care 




• Family medicine 
practitioners often are 
uncomfortable delivering 








• Clinical reminders may 
be beneficial in 
providing preventative 
care for the IBD patient 
in the PCP setting 









to Fill the 
Primary Care 













• Most nurse practitioners 
live in areas with a high 
ratio of physician 
providers 
• 40% of NP are 55 and 
older 
• Only 8 of 23 NP schools 
are in primary care 
shortage areas 
• Many NPs plan on 
moving out of state 
Limitations 
• Data is self-reported 
• A causal relationship 
cannot be interpreted due 
to analyses being cross-
sections 
• Categorization of 
counties above or below 
statewide averages for a 
provider to patient ratio 




















vaccinating the IBD 
patient. 
Assess the barriers 
preventing 
vaccination. 







Members of the 





• 52% (56) asked about 
vaccination status most 
or all the time 
• 64% (69) believed it was 
PCP responsibility to 
inquire about vaccination 
• 83% (90) believed it was 
the PCP responsibility to 
vaccinate 
• 66-88% recommended 
the appropriate 
vaccinations for IBD 
patients not on 
immunosuppressant 
therapy 
• 20-30% incorrectly 
recommended live 
vaccines to their  
immunocompromised 
IBD patients 
• 24-35% incorrectly did 
not give three queried 
live, attenuated vaccines 
to the immunocompetent 
patient 
• 66% (71) recommended 
the HPV to their 
immunocompetent 
patients 
• 47% (51) recommended 
the HPV to their 
immunosuppressed 
patient 
• 12% (13) correctly 
identified vaccines for 
both immunocompetent 




• Rate of survey response 
(11%) 
Biases 
• Response bias 
• Prize offered 
• Possible underestimation 
of gastroenterologist 
knowledge of vaccines 
• No differentiation 





















IBD Using a 







To assess if the 






139 GI outpatients in 
the Hunter Holmes 
McGuire VA 
Medical Center in 
Richmond, Virginia 
Retrospective 
chart review  
Results 
• All preventative care 
recommendation 
improved except for that 
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Appendix B 
 
Data Collection Tool 
Chart Review Items Which Patients How Often Categories 
Age 
 












































             
      
        
Diagnosis 
 








Years of Diagnosis 
 
  Unknown 
< 8 years 















Last Visit to PCP 
 
All Patients NA Unknown 
≤1 year 






































































Hepatitis A  All patients One time  







Hepatitis B  All patients One time  
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Pneumococcal PVC13  
 
 
Age ≥ 65 or  
19 ≥ & 
immunosuppressed 









Pneumococcal PPSV23 Age ≥ 65 or  
19 ≥ & 
immunosuppressed 















DEXA Scan Women  65 ≥ and  
All at high risk  









Rx of Calcium &  
Vitamin D  
All patients on oral 
steroids or deficient 









Colonoscopy All patients with 



































Mammogram All women age 40-74  
All women Age ≥ 75 










Tobacco Use and 
Cessation 




















B12  All patients with ileal 






































PPD or IGRA All patients once  Once 
(Annually if exposed 
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Appendix C 
 
Name: ____________________________________      DOB: ___________________________ 
Primary Care Provider: _______________________      Last Appointment w/ PCP: __________ 
Diagnosis: _________________________________      Immunosuppression: _______________ 
Immunosuppression (Corticosteroids, immunomodulators, biologics, and thiopurines) 
Vaccine Preventable Illnesses (Non-Live) Ordered Referred Date 
Done 
Herpes Zoster (Shingles – Non-Live Recombinant Vaccine RZV) 
Recommended for all patients> 50 or any taking immunosuppressive 
therapy or starting tofacitinib. (2 dose series @ least 4 weeks apart) 
   
Tetanus, Diphtheria, and Pertussis (Non-Live Vaccine) 
All patients not vaccinated should be given Tdap, followed by a  
Td booster every 10 years.  
   
Influenza (Non-Live Vaccine) 
Annually one dose to all patients during flu season. Avoid live 
intranasal vaccine in immunosuppressed patients. 
   
HPV (Non-Live Vaccine) 
Given to all patients (male and female) regardless of 
immunosuppression for the prevention of cervical and anal cancer. 
Three doses series approved for females and males ages 9-26.  
   
Hepatitis A (Non-Live Vaccine) 
Check HAV IgG. Give to all patients not immune. (2-dose series:  
Havrix or Vaqta or 3-dose series: Twinrix [HepA-HepB])  
   
Hepatitis B (Non-Live Vaccine)  
Before initiating anti-TNF therapy, check hepatitis B surface antigen, 
hepatitis B surface antibody, hepatitis B core antibody, and if the 
patient is non-immune, consider vaccinating with non-live hepatitis  
B vaccine (3 doses). Withhold anti-TNF treatment and check PCR if 
active viral infection or core Ab positive until an active infection is  
ruled out or treated appropriately. (2-dose Heplisav-B; 3-dose  
Engerix-B, Recombivax HB, or Twinrix [HepA-HepB]). 
   
Meningococcal Meningitis Group B (Non-Live Vaccine)  
Vaccinate at-risk patients such as college students age 16-23 if not 
formerly vaccinated regardless of immunosuppression. 
   
Pneumococcal Pneumonia (Non-Live Vaccine) 
All patients ≥ 65 years of age and not immunosuppressed: Consider 
vaccination with PSV23 (Pneumovax®). If on or planning 
immunosuppression therapy and are ≥ 19, vaccinate with PCV13 
(Prevnar®) followed by PSV23 (Pneumovax®) ≥ 8 weeks later. Then 
after five years, follow with the PSV23 booster. 
   
Live Vaccines (Not recommended with immunosuppression) 
 
Ordered Referred Date 
Done 
Varicella (Chicken Pox Live Vaccine) 
For all patients, not immune. Check Varicella-Zoster Virus IgG. 
And if negative, consider vaccinating (2-dose series 4-8 weeks 
apart). Can be considered in patients on “low-dose” 
immunosuppression (prednisone ≤ 20 mg/day or MTX, 6-MP, 
azathioprine), BUT not patients on Biologics. May give > 4 
weeks before starting biologics. 
 
   
Preventative Screening Evaluation Tool for IBD 
Patients 
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MMR (Live Vaccine) 
All patients. Contraindicated in immunosuppressed patients. 
Vaccinate ≥ 4 weeks of initiating immunosuppressants 
   
Bone Health Ordered Referred Date 
Done 
Vitamin D 25-OH Level  
Check once in all patients and supplement if level deficient/insufficient 
   
DEXA Scan for bone density 
Assess bone density for women ≥ 65 or for the following patients 
1. Those with > 3 months steroid use  
2. Inactive disease with   
• Past chronic steroid use of ≥ 1 year within the past 2 years  
• Maternal history of osteoporosis  
• Malnourished or very thin  
• Amenorrheic  
• All postmenopausal women, irrespective of disease status. 
   
Prescription of Calcium & Vitamin D  
A prescription of calcium and vitamin D for all patients with 
each treatment of oral corticosteroids and if levels of vitamin D are 
deficient 
   
Cancer Screening Ordered Referred Date 
Done 
Colonoscopy for Cancer  
For all extensive disease (ulcerative colitis beyond the rectum or   
Crohn's in at least 1/3 of the colon) > than 8 years every 1-3                   
years. 
   
Pap Smear for Cervical Cancer   
Annual Pap smear for all women on immunosuppressive   
therapy.  
   
Full body assessment by a dermatologist for skin cancer 
A yearly visual exam of the skin by a dermatologist if   
Immunocompromised. Recommend sun exposure safety 
measures. 
   
**Mammogram for Breast Cancer  
Women age 40-74 should receive yearly mammograms.  
Age ≥ 75 if the life expectancy of 10 years or >. 
   
Other Screenings Ordered Referred Date 
Done 
Tobacco Use and Cessation: Review at each visit    
Depression Screening: PHQ 2 at each visit    
**Alcohol Screening: Review at each visit    
Nutritional Assessment: Obtain a B12 level if ileal disease  
or resection, and iron panel. 
   
**Lipid Panel: Annually for hypertensive and hyperlipidemia  
    patients  
   
**Diabetes Screening:  Annually for hypertensive and  
    hyperlipidemia patients  
   
PPD or IGRA: Once for all patients before initiating anti-  
TNF or anti-IL-12/23 and then repeat annually if potential 
exposure to TB or in a high-risk region. 
   
Adaptive from Cornerstones Health IBD Checklist for Monitoring & Prevention. Retrieved from https://www.cornerstoneshealth.org/wp-content/uploads/2019/05/Checklist-for-
Monitoring-Prevention-2018.pdf, and the Crohn’s & Colitis Foundation Retrieved from https://www.crohnscolitisfoundation.org/sites/default/files/2019-
09/Health%20Maintenance%20Checklist%202019-3.pdf with recommendations from the American College of Gastroenterology Clinical Guidelines. 
** These screenings are part of general preventative screenings but were included due to importance in preventative care and ease of screening. RZV: Recombinant Zoster 
Vaccine; MMR: measles, mumps, and rubella; Tdap: tetanus and diphtheria toxoids with acellular pertussis Td: tetanus and diphtheria; HPV: Human Papilloma Virus; PVC13: 
pneumococcal conjugate vaccine; PPSV23: pneumococcal polysaccharide vaccine DEXA: dual-energy X-ray absorptiometry; PAP: Papanicolaou; PHQ 2: Patient Health 
Questionnaire; PPD: purified protein derivative; IGRA: Interferon Gamma Release Assay. 
Signature: _________________________                               Date: _________________ 
